Theravance Biopharma (TBPH) Change in Account Payables (2013 - 2026)
Theravance Biopharma (TBPH) reported Change in Account Payables of -$1.5 million for Q1 2026, down 984.34% year-over-year from $166000.0 in Q1 2025, and down 513.52% quarter-over-quarter from $355000.0 in Q4 2025.
Theravance Biopharma (TBPH) Change in Account Payables (2013 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has 14 years of Change in Account Payables data on file, last reported at -$1.5 million in Q1 2026.
- Change in Account Payables for Q1 2026 came in at -$1.5 million, down 984.34% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.3 million (down 278.69% YoY), and the FY2025 annual result was $326000.0, down 56.53% from the prior year.
- Change in Account Payables fell to -$1.5 million in Q1 2026 per TBPH's latest filing, from $355000.0 in the prior quarter.
- Over five years, Change in Account Payables peaked at $2.2 million in Q3 2022 and troughed at -$3.8 million in Q4 2022.
- A 5-year average of -$117529.4 and a median of $166000.0 in 2025 frame the typical range for Change in Account Payables.
- On a YoY basis, Change in Account Payables climbed as much as 344.55% in 2025 and fell as far as 36550.0% in 2025.
- A 5-year view of Change in Account Payables shows it stood at -$3.8 million in 2022, then surged by 90.75% to -$348000.0 in 2023, then soared by 326.44% to $788000.0 in 2024, then sank by 54.95% to $355000.0 in 2025, then slumped by 513.52% to -$1.5 million in 2026.
- Business Quant data shows TBPH's Change in Account Payables at -$1.5 million in Q1 2026, $355000.0 in Q4 2025, and $538000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -9.42 Mn |
| 10 | Theravance Biopharma | 835.85 Mn | 441.18 Mn | - | -1.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.47 Mn |
| Mar 31, 2026 | -1.47 Mn |
| Dec 31, 2025 | 355,000.00 |
| Dec 31, 2025 | 355,000.00 |
| Sep 30, 2025 | 538,000.00 |
| Sep 30, 2025 | 538,000.00 |
| Jun 30, 2025 | -733,000.00 |
| Jun 30, 2025 | -733,000.00 |
| Mar 31, 2025 | 166,000.00 |
| Mar 31, 2025 | 166,000.00 |
| Dec 31, 2024 | 788,000.00 |
| Dec 31, 2024 | 788,000.00 |
| Sep 30, 2024 | -220,000.00 |
| Sep 30, 2024 | -220,000.00 |
| Jun 30, 2024 | -2,000.00 |
| Jun 30, 2024 | -2,000.00 |
| Mar 31, 2024 | 184,000.00 |
| Mar 31, 2024 | 184,000.00 |
| Dec 31, 2023 | -348,000.00 |
| Dec 31, 2023 | -348,000.00 |